DNA Stock Chart & Stats
$170.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$110.00 - $289.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$8.41B
Enterprise Value$395.48
Total Cash (Recent Filing)$373.46M
Total Debt (Recent Filing)$410.70M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Aug 06, 2026EPS Estimate
-15.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding53,361,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$210.11Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~81% gross margins show the foundry model captures high per-revenue value, creating structural operating leverage. As revenue recovers, high gross margins allow incremental revenue to flow to the bottom line faster, improving long-term profitability potential and cash generation.
Nebula Platform ScaleRapid rack expansion, broad device integrations and many protocols signal deepening platform capabilities and customer engagement. Scale and integrations raise switching costs and throughput economics, increasing the probability that development work converts to recurring platform services and downstream participation revenue over time.
Strong Liquidity PositionA $373M cash stockpile with no bank debt provides runway to fund Nebula scale-up, AI integration and channel development without immediate refinancing. This flexibility reduces short-term solvency risk and enables strategic investments that support durable commercial execution and product maturation.
Bears Say
Sharp Revenue ContractionA multi-period revenue decline (TTM -28.4% and Q1 -49% YoY) shows structural demand or contract execution issues. Persistent top-line weakness undermines the leverage from high gross margins, delays breakeven, forces reliance on milestone payments, and increases financing and execution risk over the medium term.
Ongoing Cash BurnLarge negative OCF and FCF despite cost reductions means the company still depends on external capital to sustain operations. Continued burn constrains strategic optionality, raises dilution or refinancing risk, and limits the firm's ability to convert R&D and scale investments into a self-sustaining business without material revenue improvement.
Unproven Monetization & Scaling RiskManagement acknowledges technical 'things break' during Nebula scaling and that channels (cloud lab, AWS/Benchling/Tamarind, DataPoints) are nascent. Executional and commercialization uncertainty means investment may not translate to predictable, repeatable revenue in the 2–6 month horizon, delaying margin recovery.
DNA FAQ
What was Ginkgo Bioworks Holdings, Inc.’s price range in the past 12 months?
Ginkgo Bioworks Holdings, Inc. lowest stock price was $110.00 and its highest was $289.00 in the past 12 months.
What is Ginkgo Bioworks Holdings, Inc.’s market cap?
Ginkgo Bioworks Holdings, Inc.’s market cap is $8.41B.
When is Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date?
Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were Ginkgo Bioworks Holdings, Inc.’s earnings last quarter?
Ginkgo Bioworks Holdings, Inc. released its earnings results on May 07, 2026. The company reported -$24.337 earnings per share for the quarter, missing the consensus estimate of -$21.203 by -$3.134.
Is Ginkgo Bioworks Holdings, Inc. overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings, Inc.’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
What is Ginkgo Bioworks Holdings, Inc.’s EPS estimate?
Ginkgo Bioworks Holdings, Inc.’s EPS estimate is -15.67.
How many shares outstanding does Ginkgo Bioworks Holdings, Inc. have?
Ginkgo Bioworks Holdings, Inc. has 53,361,140 shares outstanding.
What happened to Ginkgo Bioworks Holdings, Inc.’s price movement after its last earnings report?
Ginkgo Bioworks Holdings, Inc. reported an EPS of -$24.337 in its last earnings report, missing expectations of -$21.203. Following the earnings report the stock price went down -13.826%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings, Inc.?
Currently, no hedge funds are holding shares in MX:DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$210.11 (― Downside)
$210.11 (― Downside)
Blogger Sentiment
Neutral
MX:DNA Sentiment 50%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q1 2026
0:00 / 0:00
DNA Stock 12 Month Forecast
Average Price Target
$210.11